CLX at a glance
Clorox (CLX, SEC CIK 21076) filed its latest 10-K annual report on August 7, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as November 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended June 30, 2025 (FY2025), Clorox (CLX) reported revenue of $7.1 billion (up 0.2% from FY2024) and net income of $810.0 million. Diluted EPS was $6.52.
- As of September 30, 2026, 45 institutional investment managers tracked by SignalX reported holding Clorox (CLX) shares worth $4.5 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Breber Pierre R on November 4, 2026 of 4,000 shares at $100.06 per share.
- In the last 90 days, CLX insiders reported 1 open-market purchase ($400K) and 0 open-market sales ($0) on Form 4, a net purchase of $400K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $7.1B
- +0.2% vs prior year
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$400K
- 13F holders
- 45 funds
- $4.5B · −2 vs prior quarter
- Latest 8-K
- Nov 19, 2026
- Item 5.07
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jun 30, 2026
Management Discussion & Analysis
- Revenue details not explicitly stated; focus on cash flows: Operating cash flow $612M in 2026 vs. $981M in 2025, decrease due to Venture Agreement and lower cash earnings
- Operating margin or profit metrics not provided; adjusted free cash flow 13.1% of net sales in 2026 vs. 10.7% in 2025
- Best performing segment details not disclosed; largest cash outflow from investing activities $2,301M in 2026 mainly due to GOJO acquisition
- Financing cash flow $1,668M in 2026 vs. $(924)M in 2025 driven by higher borrowings for GOJO; Stock repurchases $254M; Dividends per share $4.96 in 2026, up from $4.88 in 2025
- Management expects sufficient liquidity supported by positive future cash flow, strong credit ratings (S&P: A-2/BBB+), and available revolving credit lines totaling $1,964M
Business Overview
- Core business model: Multinational manufacturer and marketer of consumer and professional products with $6.7B net sales, 9,200 employees across 25 countries (FY 2026)
- New acquisition: April 2026 acquisition of GOJO, expanding health and hygiene segment and B2B channels, including Purell brand and dispensing systems
- Strategic shift: Expiration of P&G joint venture in January 2026; acquired full ownership of Glad business, increasing standalone operational responsibility
- Quantitative metric: $580 million invested in transformational technologies including new ERP system completed in Q3 FY 2026; employee count increased due to GOJO acquisition
- Noteworthy fact: Recordable incident rate (RIR) of 0.63 in FY 2026, significantly below 2024 U.S. goods manufacturing average of 2.7, highlighting strong employee safety performance
AI summary of the CLX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $1,905M, up 33% YoY from $1,429M, driven by GOJO acquisition and lapping ERP-related shipment impacts
- Gross margin 40.4% vs 41.7% YoY, down 130 basis points from higher commodity, manufacturing and logistics costs
- Best segment: Health and Wellness sales up 55%, adjusted EBIT up 69%; worst: International sales up 11%, adjusted EBIT up 63%
- Operating cash flow $143M vs $93M YoY; financing outflows $68M, with $1,175M debt primarily funding GOJO acquisition
- Outlook: volatile, challenging environment; tariff, consumer spending, commodity and geopolitical headwinds, with continued brand investment and GOJO integration Candida
AI summary of the CLX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.07: Submission of Matters to a Vote of Security Holders
- All 10 director nominees elected, with support ranging from 95.2% to 97.4% of votes cast
- Executive compensation approved on an advisory basis, receiving 92.0% of votes cast
Item 2.02: Results of Operations and Financial Condition
- Fiscal Q1 2026 results for quarter ended September 30, 2026
- Full financial results and management commentary in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Supplemental financial information for fiscal year 2026, provided in Exhibit 99.2
- Exhibit may contain additional operating or financial metrics relevant to investor analysis
Item EX-99.1: Item EX-99.1
- Q1 FY2027 net sales rose 33% to $1.91B, with GOJO contributing 15 points and ERP-transition comparisons contributing materially to organic growth
- Adjusted EPS increased 82% to $1.55, while gross margin fell 130 basis points to 40.4% from higher commodity and logistics costs
Item EX-99.2: Item EX-99.2
- Q1 FY2027 net sales $1.905B, up 33%, with 15% from GOJO acquisition and 18% organic growth
- Health and Wellness led growth at 62%, including 39% acquisition impact and 23% organic growth
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Fabian Garcia becomes CEO and director January 5, 2027, bringing Unilever, Revlon and Colgate-Palmolive leadership experience
- Linda Rendle exits as CEO, Chair and director, remaining senior advisor through April 2, 2027 at $1,350,000 base salary
Item 7.01: Regulation FD Disclosure
- CEO appointment: Mr. Garcia named chief executive officer effective October 29, 2026
- Leadership transition creates potential strategic and execution changes for Clorox
Item EX-99.1: Item EX-99.1
- Fabian Garcia appointed CEO effective January 5, 2027, succeeding Linda Rendle
- Garcia joins Clorox’s board, while Matthew Shattock becomes independent chair
AI summaries of CLX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CLX
Don't miss the next CLX filing
- Alerts as it files. A push when CLX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CLX, by share count.
- Ask anything. An AI agent that reads every CLX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Breber Pierre R | Buy | Nov 4, 2026 | 4,000 | $100.06 |
| Marriner Kirsten | F | Oct 5, 2026 | 2,142 | $80.41 |
| Barton Nina | F | Oct 5, 2026 | 1,106 | $80.41 |
| Rendle Linda J | A | Oct 5, 2026 | 29,352 | $80.41 |
| Marriner Kirsten | A | Oct 5, 2026 | 6,637 | $80.41 |
| Marriner Kirsten | F | Oct 5, 2026 | 1,951 | $80.41 |
| Bellet Luc | F | Oct 5, 2026 | 580 | $80.41 |
| Bellet Luc | A | Oct 5, 2026 | 1,677 | $80.41 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $7.1B | $7.1B |
| Gross Profit | $2.9B | $3.0B | $3.2B |
| Net Income | - | $280.0M | $810.0M |
| Gross Margin | - | 43.0% | 45.2% |
| Net Margin | - | 3.9% | 11.4% |
| Balance Sheet | |||
| Total Assets | $5.9B | $5.8B | $5.6B |
| Equity | - | $328.0M | $321.0M |
| ROE | - | 85.4% | 252.3% |
| Per Share | |||
| EPS | $1.20 | $2.25 | $6.52 |
| Cash Flow | |||
| Operating CF | - | $695.0M | $981.0M |
| CapEx | $228.0M | $212.0M | $220.0M |
Source: XBRL data in Clorox (CLX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CLX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 45 | $4.50B |
| Q2 2026 | 47 | $5.40B |
| Q1 2026 | 48 | $5.59B |
| Q4 2025 | 46 | $5.57B |
| Q3 2025 | 47 | $6.88B |
| Q2 2025 | 47 | $6.51B |
| Q1 2025 | 46 | $5.69B |
| Q4 2024 | 44 | $5.67B |
- Two Sigma Investments+3.62M (+6658%)
- Morgan Stanley+541.0K (+24%)
- Dimensional Fund Advisors+479.5K (+40%)
- Invesco Ltd+284.6K (+5%)
- Raymond James Financial+253.0K (+36%)
- BlackRock−1.92M (-19%)
- Millennium Management−1.08M (-52%)
- State Street Corp−709.2K (-8%)
- Goldman Sachs Group−489.9K (-45%)
- Northern Trust−384.7K (-24%)
- Renaissance Technologies LLC+28.2K
- Marex Group plc+3.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 370 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CLX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 19, 2026 | - | Analysis | - |
| 4 | Nov 5, 2026 | - | - | - |
| 10-Q | Nov 2, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 10-K | Aug 7, 2026 | Jun 30, 2026 | Analysis |
Related Consumer Staples companies
- ACI · Albertsons Companies IncRetail-Grocery Stores
- MO · AltriaCigarettes
- ANDE · Andersons, Inc.Wholesale-Farm Product Raw Materials
- BUD · Anheuser-Busch InBev SA/NVMalt Beverages
- ADM · Archer Daniels MidlandFats & Oils
- ARKO · ARKO Corp.Retail-Convenience Stores
- BGS · B&G Foods, Inc.Food and Kindred Products
- BYND · BEYOND MEAT, INC.Food and Kindred Products
CLX SEC filings: frequently asked questions
Are CLX insiders buying or selling?
In the last 90 days, Clorox (CLX) officers, directors and 10% owners reported 1 open-market purchase worth $400,251 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CLX stock?
As of September 30, 2026, the largest Clorox (CLX) holders among the 13F filers tracked by SignalX were BlackRock ($657.9 million), Vanguard Capital Management LLC ($642.2 million), State Street Corp ($625.7 million), Invesco Ltd ($509.9 million), Vanguard Portfolio Management LLC ($458.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CLX's revenue in fiscal year 2025?
For the fiscal year ended June 30, 2025 (FY2025), Clorox (CLX) reported revenue of $7.1 billion (up 0.2% from FY2024) and net income of $810.0 million. Diluted EPS was $6.52. The figures come from the XBRL data in the 10-K.
What did CLX report in its latest 8-K?
Clorox (CLX) filed an 8-K on November 19, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). All 10 director nominees elected, with support ranging from 95.2% to 97.4% of votes cast.
What are the latest CLX SEC filings?
Clorox (CLX) filed its latest 10-K annual report on August 7, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on November 5, 2026.
What is CLX's SEC CIK number?
Clorox (CLX)'s SEC Central Index Key (CIK) is 21076. EDGAR lists every CLX filing under that number.
Ask anything about CLX
The research agent reads CLX's filings, financials, insider trades and 13F holders, then answers with sources.